

Intravenous cyclophosphamide	Oral cyclophosphamide
<ul style="list-style-type: none"> • Patients who already have a moderate cumulative dose of cyclophosphamide • Patients with lower white blood cell counts • Patients with ready access to an infusion center • Patients who may have trouble adhering to an oral regimen 	<ul style="list-style-type: none"> • Patients for whom cost is an important factor • Patients who do not have easy access to an infusion center • Patients for whom a self-administered oral regimen will not be difficult

Figure 8 | Considerations for the route of administration of cyclophosphamide for AAV. AAV, ANCA-associated vasculitis. ANCA, antineutrophil cytoplasmic antibody.